REIT - Office
Compare Stocks
2 / 10Stock Comparison
ARE vs AMGN
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - General
ARE vs AMGN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | REIT - Office | Drug Manufacturers - General |
| Market Cap | $7.93B | $178.70B |
| Revenue (TTM) | $2.90B | $37.24B |
| Net Income (TTM) | $-1.02B | $7.80B |
| Gross Margin | 68.2% | 71.5% |
| Operating Margin | -42.8% | 31.6% |
| Forward P/E | 79.2x | 14.8x |
| Total Debt | $12.76B | $54.60B |
| Cash & Equiv. | $549M | $9.13B |
ARE vs AMGN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Alexandria Real Est… (ARE) | 100 | 29.8 | -70.2% |
| Amgen Inc. (AMGN) | 100 | 144.1 | +44.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ARE vs AMGN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ARE is the clearest fit if your priority is income & stability.
- Dividend streak 15 yrs, beta 0.95, yield 11.7%
- 11.7% yield, 15-year raise streak, vs AMGN's 2.9%
AMGN carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 9.9%, EPS growth 88.2%, 3Y rev CAGR 11.8%
- 161.5% 10Y total return vs ARE's -7.5%
- Lower volatility, beta 0.60, current ratio 1.14x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 9.9% revenue growth vs ARE's -2.6% | |
| Value | Lower P/E (14.8x vs 79.2x) | |
| Quality / Margins | 20.9% margin vs ARE's -35.3% | |
| Stability / Safety | Beta 0.60 vs ARE's 0.95 | |
| Dividends | 11.7% yield, 15-year raise streak, vs AMGN's 2.9% | |
| Momentum (1Y) | +26.0% vs ARE's -30.3% | |
| Efficiency (ROA) | 8.6% ROA vs ARE's -2.9%, ROIC 14.8% vs -2.7% |
ARE vs AMGN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ARE vs AMGN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
AMGN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AMGN is the larger business by revenue, generating $37.2B annually — 12.8x ARE's $2.9B. AMGN is the more profitable business, keeping 20.9% of every revenue dollar as net income compared to ARE's -35.3%. On growth, AMGN holds the edge at +5.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $2.9B | $37.2B |
| EBITDAEarnings before interest/tax | $74M | $15.6B |
| Net IncomeAfter-tax profit | -$1.0B | $7.8B |
| Free Cash FlowCash after capex | $1.4B | $8.6B |
| Gross MarginGross profit ÷ Revenue | +68.2% | +71.5% |
| Operating MarginEBIT ÷ Revenue | -42.8% | +31.6% |
| Net MarginNet income ÷ Revenue | -35.3% | +20.9% |
| FCF MarginFCF ÷ Revenue | +48.4% | +23.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -9.7% | +5.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +31.9% | +4.4% |
Valuation Metrics
ARE leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, AMGN's 14.1x EV/EBITDA is more attractive than ARE's 135.9x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $7.9B | $178.7B |
| Enterprise ValueMkt cap + debt − cash | $20.1B | $224.2B |
| Trailing P/EPrice ÷ TTM EPS | -5.43x | 23.27x |
| Forward P/EPrice ÷ next-FY EPS est. | 79.22x | 14.83x |
| PEG RatioP/E ÷ EPS growth rate | — | 7.91x |
| EV / EBITDAEnterprise value multiple | 135.94x | 14.15x |
| Price / SalesMarket cap ÷ Revenue | 2.67x | 4.86x |
| Price / BookPrice ÷ Book value/share | 0.41x | 20.73x |
| Price / FCFMarket cap ÷ FCF | 5.61x | 22.06x |
Profitability & Efficiency
AMGN leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
AMGN delivers a 89.4% return on equity — every $100 of shareholder capital generates $89 in annual profit, vs $-5 for ARE. ARE carries lower financial leverage with a 0.67x debt-to-equity ratio, signaling a more conservative balance sheet compared to AMGN's 6.31x. On the Piotroski fundamental quality scale (0–9), AMGN scores 7/9 vs ARE's 5/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -5.0% | +89.4% |
| ROA (TTM)Return on assets | -2.9% | +8.6% |
| ROICReturn on invested capital | -2.7% | +14.8% |
| ROCEReturn on capital employed | -3.6% | +16.0% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.67x | 6.31x |
| Net DebtTotal debt minus cash | $12.2B | $45.5B |
| Cash & Equiv.Liquid assets | $549M | $9.1B |
| Total DebtShort + long-term debt | $12.8B | $54.6B |
| Interest CoverageEBIT ÷ Interest expense | -4.37x | 5.02x |
Total Returns (Dividends Reinvested)
AMGN leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AMGN five years ago would be worth $14,871 today (with dividends reinvested), compared to $3,937 for ARE. Over the past 12 months, AMGN leads with a +26.0% total return vs ARE's -30.3%. The 3-year compound annual growth rate (CAGR) favors AMGN at 15.2% vs ARE's -21.1% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -4.9% | +1.8% |
| 1-Year ReturnPast 12 months | -30.3% | +26.0% |
| 3-Year ReturnCumulative with dividends | -50.8% | +52.8% |
| 5-Year ReturnCumulative with dividends | -60.6% | +48.7% |
| 10-Year ReturnCumulative with dividends | -7.5% | +161.5% |
| CAGR (3Y)Annualised 3-year return | -21.1% | +15.2% |
Risk & Volatility
AMGN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AMGN is the less volatile stock with a 0.60 beta — it tends to amplify market swings less than ARE's 0.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMGN currently trades 84.6% from its 52-week high vs ARE's 51.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.95x | 0.60x |
| 52-Week HighHighest price in past year | $88.24 | $391.29 |
| 52-Week LowLowest price in past year | $39.41 | $261.43 |
| % of 52W HighCurrent price vs 52-week peak | +51.9% | +84.6% |
| RSI (14)Momentum oscillator 0–100 | 46.1 | 37.9 |
| Avg Volume (50D)Average daily shares traded | 2.4M | 2.5M |
Analyst Outlook
ARE leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates ARE as "Hold" and AMGN as "Buy". Consensus price targets imply 20.0% upside for ARE (target: $55) vs 5.9% for AMGN (target: $351). For income investors, ARE offers the higher dividend yield at 11.67% vs AMGN's 2.86%.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $55.00 | $350.76 |
| # AnalystsCovering analysts | 24 | 38 |
| Dividend YieldAnnual dividend ÷ price | +11.7% | +2.9% |
| Dividend StreakConsecutive years of raises | 15 | 15 |
| Dividend / ShareAnnual DPS | $5.35 | $9.45 |
| Buyback YieldShare repurchases ÷ mkt cap | +2.6% | 0.0% |
AMGN leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ARE leads in 2 (Valuation Metrics, Analyst Outlook).
ARE vs AMGN: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is ARE or AMGN a better buy right now?
For growth investors, Amgen Inc.
(AMGN) is the stronger pick with 9. 9% revenue growth year-over-year, versus -2. 6% for Alexandria Real Estate Equities, Inc. (ARE). Amgen Inc. (AMGN) offers the better valuation at 23. 3x trailing P/E (14. 8x forward), making it the more compelling value choice. Analysts rate Amgen Inc. (AMGN) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ARE or AMGN?
On forward P/E, Amgen Inc.
is actually cheaper at 14. 8x.
03Which is the better long-term investment — ARE or AMGN?
Over the past 5 years, Amgen Inc.
(AMGN) delivered a total return of +48. 7%, compared to -60. 6% for Alexandria Real Estate Equities, Inc. (ARE). Over 10 years, the gap is even starker: AMGN returned +161. 5% versus ARE's -7. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ARE or AMGN?
By beta (market sensitivity over 5 years), Amgen Inc.
(AMGN) is the lower-risk stock at 0. 60β versus Alexandria Real Estate Equities, Inc. 's 0. 95β — meaning ARE is approximately 58% more volatile than AMGN relative to the S&P 500. On balance sheet safety, Alexandria Real Estate Equities, Inc. (ARE) carries a lower debt/equity ratio of 67% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ARE or AMGN?
By revenue growth (latest reported year), Amgen Inc.
(AMGN) is pulling ahead at 9. 9% versus -2. 6% for Alexandria Real Estate Equities, Inc. (ARE). On earnings-per-share growth, the picture is similar: Amgen Inc. grew EPS 88. 2% year-over-year, compared to -568. 9% for Alexandria Real Estate Equities, Inc.. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ARE or AMGN?
Amgen Inc.
(AMGN) is the more profitable company, earning 21. 0% net margin versus -48. 2% for Alexandria Real Estate Equities, Inc. — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMGN leads at 29. 1% versus -40. 5% for ARE. At the gross margin level — before operating expenses — AMGN leads at 70. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ARE or AMGN more undervalued right now?
On forward earnings alone, Amgen Inc.
(AMGN) trades at 14. 8x forward P/E versus 79. 2x for Alexandria Real Estate Equities, Inc. — 64. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARE: 20. 0% to $55. 00.
08Which pays a better dividend — ARE or AMGN?
All stocks in this comparison pay dividends.
Alexandria Real Estate Equities, Inc. (ARE) offers the highest yield at 11. 7%, versus 2. 9% for Amgen Inc. (AMGN).
09Is ARE or AMGN better for a retirement portfolio?
For long-horizon retirement investors, Amgen Inc.
(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 60), 2. 9% yield, +161. 5% 10Y return). Both have compounded well over 10 years (AMGN: +161. 5%, ARE: -7. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ARE and AMGN?
These companies operate in different sectors (ARE (Real Estate) and AMGN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ARE is a small-cap income-oriented stock; AMGN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.